Answers are grounded in this paper and cite their sources.
Background: Fragmented care pathways for thyroid nodular disease prolong time to decision and increase costs. “Onestop” clinics (OSCs) integrate clinical evaluation, ultrasound, ultrasoundguided fineneedle aspiration (FNA) and, when appropriate, rapid onsite evaluation (ROSE)/telecytology in a single visit. Objective: To map organizational models of OSCs, define key performance indicators (KPIs), and summarize outcomes (time, visits, adequacy, repeat FNA, costs, patient satisfaction, safety). Methods: Scoping review following PRISMAScR and JBI guidance. MEDLINE, Scopus, and Web of Science were searched (2000–August 2025). We included studies that operationalized OSCs and/or reported KPIs/outcomes. Data extraction covered organizational features, protocols (ACR/EUTIRADS, Bethesda), flow metrics, FNA/ROSE adequacy, economics, satisfaction, and safety. Narrative synthesis was performed. Results: Identified OSC models consistently shorten lead time to decision and reduce the number of visits. Sample adequacy is high–especially with ROSE/telecytology–thereby lowering repeat FNA rates. Patient satisfaction is high; the safety profile of FNA remains favourable. Economic analyses indicate that the costeffectiveness of ROSE is contextdependent and greatest when baseline inadequacy is higher and/or ROSE costs are lower. A KPI set is proposed: lead time, proportion of “singlevisit” completions, Bethesda I rate, ROSE utilization, repeat FNA ≤ 90 days, cost per episode, and satisfaction. Conclusion: OSCs are an applicable, valueoriented model for thyroid diagnostics. Selective use of ROSE/telecytology and KPIdriven management enable efficient and safe implementation across diverse resource settings.
No takes yet. Share an insight, caveat, or question.
Milić et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: